MONTREAL, QUEBEC--(MARKET WIRE)--Jul 5, 2006 -- Theratechnologies Inc.(TSX:TH.TO - News) Theratechnologies announced today its financial results for the second quarter ended May 31, 2006 and reviewed recent highlights. “During the quarter, we reached all of the milestones of our Phase 3 study on TH9507 in HIV-associated lipodystrophy and we remain committed to announcing its results around the end of the year. What’s more, through a $22 million dollar financing completed in this quarter, we now stand with liquidities of $48 million and we are in good shape to complete the rest of our Phase 3 program according to plan,” said Mr. Yves Rosconi, President and Chief Executive Officer of Theratechnologies.
